CMR Surgical has raised over $200 million in a mix of equity and debt funding, with new investment from Trinity Capital and continued support from existing investors. The funds will drive global expansion of its Versius surgical robotic platform, with a key focus on launching in the U.S. following FDA clearance in October.
Versius, a small-scale robotic system designed to biomimic the human arm, features collaborative arms, an open console, and enhanced ergonomic design to reduce surgeon fatigue. The company has also introduced Versius Plus, which expands its instrument portfolio and includes advanced digital insights and fluorescent imaging capabilities.
To date, Versius has been used in over 30,000 surgical procedures worldwide. CMR Surgical is also conducting clinical trials to evaluate its use in pediatric and transoral robotic surgery.
“CMR is a competitive, well-established company with a transformative product providing clear clinical value,” said CEO Massimiliano Colella. “We are now at a pivotal stage, poised to capitalize on significant market expansion opportunities, including in the U.S.”
Follow MEDWIRE.AI for the latest in surgical robotics.
